FAQ on NanoViricides' Measles Drug Development and Broad-Spectrum Antiviral NV-387
Summary
What is NV-387 and its significance in measles treatment?
NV-387 is a broad-spectrum antiviral drug candidate developed by NanoViricides, Inc., showing potential for measles treatment due to its efficacy against viruses that utilize the HSPG infection pathway, including success in Phase I trials with no adverse events.
Why is there a need for an effective antiviral treatment for measles now?
Declining vaccination rates are increasing the risk of measles becoming endemic in the United States, underscoring the urgent need for effective antiviral treatments like NV-387.
How has NV-387 performed in trials so far?
NV-387 has completed Phase I trials with no adverse events and demonstrated strong antiviral efficacy across multiple viruses that use the HSPG infection pathway, indicating its potential effectiveness against measles.
What are the next steps for NV-387 in its development?
NV-387 is being prepared for an animal study in humanized mice, as NanoViricides, Inc. plans to advance it into Phase II human clinical trials for various respiratory viral infections, including measles.
Who is developing NV-387 and what is their background?
NanoViricides, Inc., a development-stage company specializing in antiviral therapy nanomaterials, is developing NV-387. The company leverages proprietary technology from TheraCour Pharma, Inc. for creating nanoviricide drug candidates.
Where can I find more information about NanoViricides and NV-387?
For more information, visit NanoViricides’ website at www.NanoViricides.com or the latest updates in the company’s newsroom at https://ibn.fm/NNVC.
What other viruses is NV-387 being developed to treat?
Besides measles, NV-387 is being developed as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.
What is the business model of NanoViricides, Inc.?
NanoViricides’ business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, focusing on developing nanoviricide drug candidates like NV-387 for antiviral therapy.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 118785